Hemlibra patient develops neutralizing anti-drug antibodies

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) disclosed that a hemophilia A patient who was receiving Hemlibra emicizumab-kxwh in the Phase III HAVEN 2 trial developed neutralizing anti-drug antibodies to

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE